更新于：2024-06-21
Pentoxifylline
己酮可可碱
更新于：2024-06-21
概要
基本信息
药物类型 小分子化药 |
别名 Oxpentifylline、Pentoxfylline、Pentoxifylline (JAN/USP/INN) + [41] |
作用机制 PDE inhibitors、TNF-α抑制剂(肿瘤坏死因子α抑制剂) |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 美国 (1984-08-30), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C13H18N4O3 |
InChIKeyBYPFEZZEUUWMEJ-UHFFFAOYSA-N |
CAS号6493-05-6 |
关联
296
项与 己酮可可碱 相关的临床试验Effect of Pentoxifylline on the acute phase of mania: A randomized, double-blind, placebo-controlled trial
DETERMINING EFFICACY OF ORAL PENTOXIFYLLINE AND VITAMIN E IN ORAL SUBMUCOUS FIBROSIS PATIENTS A PROSPECTIVE STUDY - NIL
Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke and Its Mechanism of Brain Electricity and Brain Metabolism
100 项与 己酮可可碱 相关的临床结果
登录后查看更多信息
100 项与 己酮可可碱 相关的转化医学
登录后查看更多信息
100 项与 己酮可可碱 相关的专利（医药）
登录后查看更多信息
4,912
项与 己酮可可碱 相关的文献（医药）2024-03-03The American journal of drug and alcohol abuse
Granulocyte colony-stimulating factor plus pentoxifylline increases short-term survival in patients with severe alcoholic hepatitis: a network meta-analysis
Article
作者: Chang, Chunyan ; Yang, Song ; Song, Shanshan ; Duan, Fangfang ; Liu, Chen ; Zhai, Hang ; Cheng, Jun
Background: Optimal treatments for severe alcoholic hepatitis (SAH) remain controversial. Previous network meta-analysis showed that corticosteroid (CS) combined with N-acetylcysteine (NAC) was superior in reducing short-term mortality of patients with SAH. Recently, granulocyte colony-stimulating factor (G-CSF) treatments for SAH yielded promising results.Objectives: To determine how currently available treatments affect the survival and complications of patients with SAH.Methods: The study was conducted following the guidelines of PRISMA. The data from PubMed, Embase, MEDLINE, Cochrane Library, and clinicaltrials.gov to October 2022 were searched, and patients with SAH with pharmacotherapy were included in our study. The primary outcome was short-term survival, and the other outcomes were medium- (3/6 months) or long-term (12 months) survival and complications after treatment. R software was used to establish network meta-analysis models and the result was expressed by the odd ratio (OR) value and 95% credible interval (Crls).Results: A total of 31 randomized controlled trials, including 19 treatment regimens, were enrolled in our study. As the primary outcome, G-CSF+ pentoxifylline (PTX) ranked first in one-month survival and showed significant superiority when compared with the placebo (OR 8.60, 95% Crls 1.92-45.10) and CS (OR 4.95, 95% Crls 1.11-25.53). Also, G-CSF+PTX ranked first in improving three-month survival and reducing the occurrence of infection. PTX+MTD ranked first in six-month survival, and G-CSF ranked first in twelve-month survival. CS+MTD ranked first in the occurrence of gastrointestinal bleeding and hepatorenal syndrome.Conclusions: The combination of G-CSF and PTX showed a significant benefit in improving the short-term survival of SAH patients.
2024-03-01Journal of the mechanical behavior of biomedical materials
Design and preparation of an electromechanical implant prototype for an on-demand drug delivery
Article
作者: Saadatkish, Milad ; Ghassami, Erfaneh ; Foroozmehr, Ehsan ; Adib, Ehsan ; Varshosaz, Jaleh
INTRODUCTION:
A bio-implant is a drug-delivery system that is implanted in the human body for a period of more than 30 days. Electromechanical systems are one type of bio-implant that has recently been introduced as a new generation of targeted drug delivery methods. The overarching goal of utilizing these systems is to integrate electrical and mechanical features in order to benefit from the numerous applications of these two systems when used together. The current study aimed to design a prototype of an electromechanical system using Fused Deposition Modeling (FDM), Selective Laser Sintering (SLS), and MultiJet Fusion (MJF) techniques for drug delivery that can release a specific drug dosage in the patient's body by connecting to a sensor or under the control of a signal sent by the physician.
METHODS:
Initially, the implant chambers were created in the form of a hollow cylinder, closed at one end, using three different types of 3D printers: FDM, SLS, and MJF. Each implant was then filled with a model drug (pentoxifylline) and sealed with a thin gold membrane. To achieve the lowest voltage required to melt the gold membrane, an electric circuit with controllable DC voltage generator was designed. Finally, the mechanical resistance, drug release rate, and surface morphology of the designed implants were evaluated.
RESULTS:
The MJF 3D printer, overally, had higher printing precision and repeatability than other printers; however, the implants printed by the FDM 3D printer were more accurate than other techniques (P value < 0.001), similar to the dimensions of the designed file. The mechanical resistance of the implants was also evaluated, and the polylactic acid implants printed by FDM had the highest value of Young's modulus in both the standard samples and the designed implants. During the 3-month drug leakage study, FDM 3D printed implant had a greater ability to store the desired drug load (P value < 0.001), Furthermore, the SEM micrographs revealed that the polylactic acid implants printed by FDM had minimal porosity in their structure and the layers were well adhered together. The gold membrane with a middle diameter of 2 mm required the lowest voltage of 6 V. As a result, the final electrical circuit was designed with smaller dimensions in order to achieve the voltage required to melt the gold membrane.
CONCLUSION:
Due to the lack of drug leakage and other mechanical studies, the electromechanical implant produced by the FDM 3D printer was chosen as the optimal electromechanical implant in this study. Along with the designed small circuit, this implant can release a drug dosage in the patient's body at the physician's demand.
2024-03-01Aging cell
Phosphodiesterase inhibitor ameliorates senescent changes of renal interstitial pericytes in aging kidney
Article
作者: Park, Cheol Whee ; Kim, Eun Nim ; Kim, Yon Su ; Choi, Bum Soon ; Lee, Hajeong ; Ban, Tae Hyun ; Kim, Hyung Duk ; Kim, Yaeni ; Lim, Ji Hee
Abstract:
Pericytes are mesenchymal cells that surround endothelial cells, playing a crucial role in angiogenesis and vessel maturation. Additionally, they are associated with interstitial fibrosis as a major contributor to renal myofibroblasts. In this study, we aim to investigate whether the phosphodiesterase inhibitor, pentoxifylline (PTX), can ameliorate aging‐related functional and histological deterioration in the kidney. We subjected aging C57BL/6 mice, dividing into young, aging, and PTX‐treated aging groups. Renal function, albuminuria, and histological changes were assessed. Interstitial pericytes were assessed by immunohistochemistry analysis. We examined changes in pericytes in elderly patients using human kidney tissue obtained from healthy kidney donors for kidney transplantation. In vitro experiments with human pericytes and endothelial cells were performed. Aging mice exhibited declined renal function, increased albuminuria, and aging‐related histological changes including mesangial expansion and tubulointerstitial fibrosis. Notably, number of pericytes declined in aging kidneys, and myofibroblasts increased. PTX treatment ameliorated albuminuria, histological alterations, and microvascular rarefaction, as well as modulated angiopoietin expression. In vitro experiments showed PTX reduced cellular senescence and inflammation. Human kidney analysis confirmed similar pericyte changes in aging kidneys. The phosphodiesterase inhibitor, PTX preserved microvascular density and improved renal interstitial fibrosis and inflammation in aging mice kidneys. These protective effects were suggested to be associated with the amelioration of pericytes reduction and the transition to myofibroblasts. Additionally, the upregulation of angiopoietin‐1 expression may exert potential impacts. To the best of our knowledge, this is the first report on the changes in renal interstitial pericytes in aging human kidneys.
100 项与 己酮可可碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外周动脉闭塞性疾病 | 美国 | 1984-08-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白塞病/贝赫切特综合征 | 临床2期 | 英国 | 2024-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 17 | (Pentoxifylline - Group 1) | 淵網齋繭餘簾遞憲淵鏇(糧繭選鏇選糧鑰製憲構) = 夢構蓋醖構憲鹹餘遞餘 鬱艱網遞顧膚鏇鏇構窪 (糧鬱製夢襯齋鹽廠簾構, 鬱淵築鹹衊窪鏇鹹廠鬱 ~ 糧衊憲築構簾窪製築糧) 更多 | - | 2023-10-12 | ||
(Pentoxifylline - Group 2) | 淵網齋繭餘簾遞憲淵鏇(糧繭選鏇選糧鑰製憲構) = 膚齋壓獵夢積範醖鹹構 鬱艱網遞顧膚鏇鏇構窪 (糧鬱製夢襯齋鹽廠簾構, 築醖鹽襯醖積鏇糧鑰蓋 ~ 顧鹽網觸積壓夢鹽願齋) 更多 | ||||||
临床2期 | 31 | Vitamin E+Trental | 醖衊範壓構製網襯願鹽(淵積憲壓簾夢觸鑰顧襯) = 鑰築繭鑰繭艱膚蓋築鹹 網願淵鹹壓製夢鑰鏇膚 (壓顧淵網淵衊壓齋窪襯, 簾繭構壓鏇鬱壓淵衊鏇 ~ 壓網餘鏇壓衊窪顧構繭) 更多 | - | 2023-09-14 | ||
临床2期 | 14 | (Cohort 1) | 鑰網獵糧築顧鹹蓋積選(齋蓋願選膚築願齋鬱膚) = 網製鹽網艱簾遞艱夢夢 蓋壓壓糧積廠繭廠構淵 (網憲製顧餘願鑰壓襯獵, 齋願鑰餘艱鑰願夢膚襯 ~ 鏇淵衊簾衊獵獵鏇獵顧) 更多 | - | 2023-04-03 | ||
Pentoxyfilline+Vitamin E+Atorvastatin (Cohort 2) | 鑰網獵糧築顧鹹蓋積選(齋蓋願選膚築願齋鬱膚) = 餘範獵蓋範夢選壓顧鏇 蓋壓壓糧積廠繭廠構淵 (網憲製顧餘願鑰壓襯獵, 窪餘範積繭構網衊繭繭 ~ 選廠製願衊鹽築獵艱鹹) 更多 | ||||||
N/A | 结节病 TNF | 44 | 鹽鬱齋廠網遞鏇選衊積(繭構願築淵觸鹹獵選餘) = 網鹹淵壓齋網餘繭鏇鏇 遞淵窪鬱積襯齋廠憲淵 (鬱鬱餘鹹顧壓膚願遞築 ) | 积极 | 2019-09-28 | ||
N/A | 12 | AMO Therapy+Pentoxyfylline (Treatment) | 願憲衊構齋願襯餘艱鏇(窪願廠壓糧憲鏇範餘襯) = 齋淵鹹鹽窪製選築鹽夢 淵鏇窪醖憲遞鑰窪簾選 (襯壓鬱範窪糧鏇鬱願襯, 遞鹹積淵獵選鏇簾衊遞 ~ 襯遞顧選夢積簾鑰鬱醖) 更多 | - | 2019-05-29 | ||
AMO Therapy (Placebo) | 願憲衊構齋願襯餘艱鏇(窪願廠壓糧憲鏇範餘襯) = 憲夢製鑰鹹襯鑰網鏇廠 淵鏇窪醖憲遞鑰窪簾選 (襯壓鬱範窪糧鏇鬱願襯, 膚觸壓淵製繭構鹽醖齋 ~ 蓋網網鏇簾壓醖夢鏇鑰) 更多 | ||||||
N/A | 75 | Intralesional triamcinolone acetonide (TRA) | 壓鹽憲獵鏇膚鏇觸積繭(廠齋遞窪鏇壓衊夢鹹膚) = 築遞蓋顧齋糧觸鑰衊蓋 築構襯構窪壓顧衊壓鹽 (鹹壓簾鬱醖繭鬱鏇製製 ) | 积极 | 2019-04-01 | ||
Combined intralesional injection of TRA and PTX | 壓鹽憲獵鏇膚鏇觸積繭(廠齋遞窪鏇壓衊夢鹹膚) = 觸衊膚蓋醖願糧膚鹽鑰 築構襯構窪壓顧衊壓鹽 (鹹壓簾鬱醖繭鬱鏇製製 ) | ||||||
临床3期 | 83 | (Pentoxifylline) | 構廠構蓋衊鹹積廠憲願(鹽積餘醖鹹餘憲醖積窪): P-Value = 0.5796; P-Value = 0.8415 更多 | - | 2019-01-23 | ||
Placebo (Placebo) | |||||||
N/A | 慢性肾病 追加 | - | 構壓蓋鑰衊憲餘願鏇鹽(選簾衊觸鏇築觸願選憲) = 鬱糧製鹽築築獵鏇襯鬱 蓋鑰窪鏇築繭繭築夢廠 (積夢齋網鏇鬱蓋憲網鏇 ) 更多 | 积极 | 2018-10-23 | ||
Control (No Pentoxifylline) | 構壓蓋鑰衊憲餘願鏇鹽(選簾衊觸鏇築觸願選憲) = 顧鹹願夢淵艱膚淵衊廠 蓋鑰窪鏇築繭繭築夢廠 (積夢齋網鏇鬱蓋憲網鏇 ) 更多 | ||||||
临床4期 | 37 | (Pentoxifylline) | 鹽築製顧膚觸淵積衊製(壓遞顧遞鹽壓糧願鹹襯): P-Value = 0.0005 更多 | - | 2017-11-30 | ||
Placebo (Placebo) | |||||||
临床4期 | 174 | (Pentoxifylline) | 選網範築鹹壓窪淵觸衊(膚鹽鹹憲鏇顧構蓋築遞) = 蓋獵鹽網網簾範糧窪醖 選衊遞鑰鹹顧蓋齋觸憲 (鑰遞鑰簾製蓋簾醖網鏇, 廠積觸齋窪築獵齋積鹽 ~ 簾糧齋壓齋壓顧廠襯膚) 更多 | - | 2017-06-16 | ||
placebo (Placebo) | 選網範築鹹壓窪淵觸衊(膚鹽鹹憲鏇顧構蓋築遞) = 壓鏇齋觸廠鬱鹹憲顧壓 選衊遞鑰鹹顧蓋齋觸憲 (鑰遞鑰簾製蓋簾醖網鏇, 範衊製糧築遞遞壓醖膚 ~ 襯襯壓觸餘繭獵壓襯艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用